专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08633315B2 Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use 有权
标题翻译：取代的羟乙基胺化合物作为β-分泌酶调节剂和使用方法
公开(公告)号：US08633315B2
公开(公告)日：2014-01-21
申请号：US13427802
申请日：2012-03-22
申请人： Wenge Zhong , Stephen Hitchcock , Patel F. Vinod , Michael Croghan , Bryant Yang
发明人： Wenge Zhong , Stephen Hitchcock , Patel F. Vinod , Michael Croghan , Bryant Yang
IPC分类号： C07D491/107 , C07D311/96 , C07D471/10
CPC分类号： C07D491/107 , C07D221/06 , C07D311/96 , C07D471/10 , C07D491/10 , C07D493/10 , C07D495/10
摘要： The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R1a, R1b, R1c, B, W, R3, R4 and R5 are defined herein. In another embodiment, the invention provides compounds of general Formula II wherein A1, A2, A3, A4, R1a, R1b, R1c, R2, R4, R5, W, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.
摘要翻译：本发明包括可用于调节β-分泌酶酶活性和用于治疗β-分泌酶介导的疾病（包括阿尔茨海默病（AD））和相关病症的新一类化合物。在一个实施方案中，化合物具有通式I，其中R 1a，R 1b，R 1c，B，W，R 3，R 4和R 5在本文中定义。在另一个实施方案中，本发明提供通式II的化合物，其中A1，A2，A3，A4，R1a，R1b，R1c，R2，R4，R5，W，X和Z如本文所定义。本发明还包括在药物组合物中用于治疗，预防或治疗与β-分泌酶蛋白活性相关的病症和病症的用途。这些疾病包括例如阿尔茨海默病（AD），认知缺陷和损伤，精神分裂症和其他类似的中枢神经系统疾病。本发明还包括式II的其它实施方案，可用于制备式I和II化合物的中间体和方法。

2. 发明授权

US08552181B2 Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use 有权
标题翻译：取代的羟乙基胺化合物作为β-分泌酶调节剂和使用方法
公开(公告)号：US08552181B2
公开(公告)日：2013-10-08
申请号：US13410201
申请日：2012-03-01
申请人： Wenge Zhong , Stephen Hitchcock , Vinod F. Patel , Michael Croghan , Thomas Dineen , Scott Harried , Daniel Horne , Ted Judd , Matthew Walker , Charles Kreiman , Patricia Lopez , Holger Monenschein , Thomas Nguyen , Matthew Weiss , Qiufen Xue , Bryant Yang , Russell Graceffa
发明人： Wenge Zhong , Stephen Hitchcock , Vinod F. Patel , Michael Croghan , Thomas Dineen , Scott Harried , Daniel Horne , Ted Judd , Matthew Walker , Charles Kreiman , Patricia Lopez , Holger Monenschein , Thomas Nguyen , Matthew Weiss , Qiufen Xue , Bryant Yang , Russell Graceffa
IPC分类号： C07D471/10 , C07D491/107 , C07D495/10
CPC分类号： C07D221/06 , C07D311/96 , C07D471/10 , C07D491/10 , C07D493/10 , C07D495/10
摘要： The present invention comprises a new class of compounds useful for the modulation of Beta-secretase activity and for the treatment of diseases, including Alzheimer's disease (AD) and related CNS conditions, mediated thereby. In one embodiment, the compounds have a general Formula I or Formula II wherein R1a-1c, B, R3-5 and W of Formula I, and R1a-1c, R2-5, A1-4, W, X, Z, m and n of Formula II are defined herein. The invention further provides compounds of Formula III and IV and sub-Formulas II-A-II-D and III-A-III-D. The compounds may be used in pharmaceutical compositions for treating, prophylactically or therapeutically, disorders related to the activity of beta-secretase protein, including without limitation, AD, cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions.
摘要翻译：本发明包括可用于调节β-分泌酶活性和用于治疗包括阿尔茨海默病（AD）和相关CNS病症在内的疾病的新一类化合物。在一个实施方案中，化合物具有通式I或式II，其中式I的R 1a-1c，B，R 5-5和W，以及R 1a-1c，R 2-5，A1-4，W，X，Z，m 并且式II的n定义在本文中。本发明进一步提供式III和IV的化合物和式II-A-II-D和III-A-III-D的化合物。该化合物可用于治疗，预防或治疗与β-分泌酶蛋白活性相关的疾病的药物组合物，包括但不限于AD，认知缺陷和损伤，精神分裂症和其它类似的中枢神经系统疾病。

3. 发明授权

US08497264B2 Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use 有权
公开(公告)号：US08497264B2
公开(公告)日：2013-07-30
申请号：US13047693
申请日：2011-03-14
申请人： Jian J. Chen , Wenge Zhong , Bryant Yang , Ryan White , Matthew Weiss , Timothy Powers , Yuan Cheng
发明人： Jian J. Chen , Wenge Zhong , Bryant Yang , Ryan White , Matthew Weiss , Timothy Powers , Yuan Cheng
IPC分类号： C07D513/10 , C07D498/20 , A61K31/547 , A61K31/5386
CPC分类号： C07D513/10 , C07D498/10 , C07D498/20 , C07D513/20
摘要： The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, R2, R7, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

4. 发明申请

US20110251190A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE 有权
标题翻译：作为β-分泌酶调节剂的螺环四环化合物及其使用方法
公开(公告)号：US20110251190A1
公开(公告)日：2011-10-13
申请号：US13047734
申请日：2011-03-14
申请人： Yuan CHENG , Ryan White , Albert Amegadzie , James Brown , Alan C. Cheng , Erin F. Dimauro , Thomas Dineen , Oleg Epstein , Vijay Keshav Gore , Jason Brooks Human , Ted Judd , Charles Kreiman , Qingyian Liu , Patricia Lopez , Vu Van Ma , Isaac Marx , Ana Minatti , Hanh Nho Nguyen , Nick A. Paras , Vinod F. Patel , Wenyuan Qian , Matthew Weiss , Qiufen Xue , Xiao Mei Zheng , Wenge Zhong
发明人： Yuan CHENG , Ryan White , Albert Amegadzie , James Brown , Alan C. Cheng , Erin F. Dimauro , Thomas Dineen , Oleg Epstein , Vijay Keshav Gore , Jason Brooks Human , Ted Judd , Charles Kreiman , Qingyian Liu , Patricia Lopez , Vu Van Ma , Isaac Marx , Ana Minatti , Hanh Nho Nguyen , Nick A. Paras , Vinod F. Patel , Wenyuan Qian , Matthew Weiss , Qiufen Xue , Xiao Mei Zheng , Wenge Zhong
IPC分类号： A61K31/538 , A61K31/436 , C07D413/14 , C07D417/14 , A61K31/444 , A61P25/00 , C07D513/10 , A61K31/4545 , C07D498/10 , A61K31/497 , A61P25/28 , A61P25/16 , C07D513/20 , A61K31/506
CPC分类号： C07D491/10 , A61K31/42 , A61K31/422 , A61K31/4439 , A61K31/506 , A61K31/5377 , C07D221/20 , C07D235/02 , C07D263/08 , C07D295/135 , C07D498/10 , C07D498/20 , C07D513/10 , C09B11/28
摘要： The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and other related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, R2, R7, X and Y of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
摘要翻译：本发明包括可用于调节β-分泌酶酶活性和用于治疗β-分泌酶介导的疾病（包括阿尔茨海默氏病（AD））和其它相关病症的新一类化合物。在一个实施方案中，化合物具有通式I，其中式I中的A1，A2，A3，A4，A5，A6，R2，R7，X和Y如本文所定义。本发明还包括在药物组合物中用于治疗，预防或治疗与β-分泌酶蛋白活性相关的病症和病症的用途。这种病症包括例如阿尔茨海默氏病，认知缺陷，认知障碍，精神分裂症和与脑上形成和/或沉积斑块相关和/或引起的其他中枢神经系统病症。本发明还包括式I的其它实施方案，可用于制备式I化合物的中间体和方法。

5. 发明申请

US20110251186A1 Amino-Oxazines and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use 有权
标题翻译：氨基 - 恶嗪和氨基 - 二氢噻嗪化合物作为β-分泌酶调节剂和使用方法
公开(公告)号：US20110251186A1
公开(公告)日：2011-10-13
申请号：US13047693
申请日：2011-03-14
申请人： Jian J. CHEN , Wenge ZHONG , Bryant YANG , Wenyuan QIAN , Patricia LOPEZ , Ryan WHITE , Matthew WEISS , Ted JUDD , Timothy POWERS , Yuan CHENG , Thomas DINEEN , Oleg EPSTEIN , Jonathan LOW , Isaac MARX , Ana Elena MINATTI , Michele POTASHMAN , Nick A. PARAS
发明人： Jian J. CHEN , Wenge ZHONG , Bryant YANG , Wenyuan QIAN , Patricia LOPEZ , Ryan WHITE , Matthew WEISS , Ted JUDD , Timothy POWERS , Yuan CHENG , Thomas DINEEN , Oleg EPSTEIN , Jonathan LOW , Isaac MARX , Ana Elena MINATTI , Michele POTASHMAN , Nick A. PARAS
IPC分类号： A61K31/547 , A61P25/28 , C07D513/10 , C07D498/20 , A61K31/5386
CPC分类号： C07D513/10 , C07D498/10 , C07D498/20 , C07D513/20
摘要： The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, R2, R7, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.
摘要翻译：本发明包括可用于调节β-分泌酶酶活性和用于治疗β-分泌酶介导的疾病（包括阿尔茨海默病（AD））和相关病症的新一类化合物。在一个实施方案中，化合物具有通式I，其中式I中的A1，A2，A3，A4，A5，A6，R2，R7，X，Y和Z如本文所定义。本发明还包括在药物组合物中用于治疗，预防或治疗与β-分泌酶蛋白活性相关的病症和病症的用途。这种病症包括例如阿尔茨海默氏病，认知缺陷，认知障碍，精神分裂症和与脑上形成和/或沉积斑块相关和/或引起的其他中枢神经系统病症。本发明还包括式I的其它实施方案，可用于制备式I化合物的中间体和方法。

6. 发明申请

US20110118250A1 BETA-SECRETASE MODULATORS AND METHODS OF USE 有权
标题翻译： BETA-SECRETASE调制器和使用方法
公开(公告)号：US20110118250A1
公开(公告)日：2011-05-19
申请号：US12909566
申请日：2010-10-21
申请人： Brian K. Albrecht , Denise Lyn Andersen , Michael Bartberger , James Brown , Ryan Brown , Stuart C. Chaffee , Yuan Cheng , Michael Croghan , Russell Graceffa , Scott Harried , Stephen Hitchcock , Randall Hungate , Ted Judd , Matthew Kaller , Charles Kreiman , Daniel La , Patricia Lopez , Craig Masse , Holger Monenschein , Thomas Nguyen , Thomas Nixey , Vinod F. Patel , Lewis Pennington , Matthew Weiss , Qiufen Xue , Bryant Yang , Wenge Zhong
发明人： Brian K. Albrecht , Denise Lyn Andersen , Michael Bartberger , James Brown , Ryan Brown , Stuart C. Chaffee , Yuan Cheng , Michael Croghan , Russell Graceffa , Scott Harried , Stephen Hitchcock , Randall Hungate , Ted Judd , Matthew Kaller , Charles Kreiman , Daniel La , Patricia Lopez , Craig Masse , Holger Monenschein , Thomas Nguyen , Thomas Nixey , Vinod F. Patel , Lewis Pennington , Matthew Weiss , Qiufen Xue , Bryant Yang , Wenge Zhong
IPC分类号： A61K31/538 , C07D405/12 , A61K31/4433 , A61K31/444 , C07D405/14 , A61K31/4439 , A61K31/506 , A61K31/497 , C07D413/12 , A61K31/5377 , A61K31/4178 , A61K31/4545 , A61K31/453 , C07D311/96 , A61K31/352 , C07D407/12 , A61K31/4709 , C07D401/12 , C07D409/12 , A61K31/422 , A61K31/4025 , C07D471/04 , A61K31/501 , A61P25/28 , A61P25/00 , A61P25/16
CPC分类号： C07D405/12 , C07D413/12
摘要： The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A, B, R3, R4, R5, i and j are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, methods of use for these compounds, including treatment of AD and related diseases, by administering the compound(s) of Formula I, or compositions including them, to a subject. The invention also comprises further embodiments of Formulas II and III, intermediates and processes useful for the preparation of compounds of the invention.
摘要翻译：本发明包括可用于调节β-分泌酶酶活性和用于治疗β-分泌酶介导的疾病（包括阿尔茨海默氏病（AD））和相关病症的新一类化合物。在一个实施方案中，化合物具有通式I，其中A，B，R 3，R 4，R 5，i和j在本文中定义。本发明还包括药物组合物，其包括一种或多种式I化合物，这些化合物的使用方法，包括治疗AD和相关疾病，通过给受试者施用式I化合物或包含它们的组合物。本发明还包括式II和III的其它实施方案，可用于制备本发明化合物的中间体和方法。

7. 发明申请

US20100120774A1 Substituted Pyrano [2,3-b] Pyridinamine compounds as beta-secretase modulators and methods of use 有权
标题翻译：取代的吡喃并[2,3-b]吡啶胺化合物作为β-分泌酶调节剂和使用方法
公开(公告)号：US20100120774A1
公开(公告)日：2010-05-13
申请号：US12291753
申请日：2008-11-12
申请人： Russell Graceffa , Matthew Kaller , Daniel La , Patricia Lopez , Vinod F. Patel , Wenge Zhong
发明人： Russell Graceffa , Matthew Kaller , Daniel La , Patricia Lopez , Vinod F. Patel , Wenge Zhong
IPC分类号： A61K31/4985 , C07D487/04 , A61K31/506 , C07D405/12 , A61P25/28
CPC分类号： C07D487/04 , C07D311/96 , C07D405/12 , C07D413/12 , C07D417/12 , C07D491/052 , C07D519/00
摘要： The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, X and Z are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.
摘要翻译：本发明包括可用于调节β-分泌酶酶活性和用于治疗β-分泌酶介导的疾病（包括阿尔茨海默病（AD））和相关病症的新一类化合物。在一个实施方案中，化合物具有通式I，其中R 1，R 2，R 3，R 4，R 5，A 1，A 2，A 3，A 4，X和Z在本文中定义。本发明还包括在药物组合物中用于治疗，预防或治疗与β-分泌酶蛋白活性相关的病症和病症的用途。这些疾病包括例如阿尔茨海默病（AD），认知缺陷和损伤，精神分裂症和其他类似的中枢神经系统疾病。本发明还包括式II的其它实施方案，可用于制备式I和II化合物的中间体和方法。

8. 发明申请

US20090036478A1 Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use 有权
标题翻译：取代的羟乙基胺化合物作为β-分泌酶调节剂和使用方法
公开(公告)号：US20090036478A1
公开(公告)日：2009-02-05
申请号：US12154497
申请日：2008-05-23
申请人： Wenge Zhong , Stephen Hitchcock , Vinod F. Patel , Michael Croghan , Thomas Dineen , Daniel Horne , Matthew Kaller , Charles Kreiman , Patricia Lopez , Holger Monenschein , Thomas Nguyen , Lewis Pennington , Qiufen Xue , Bryant Yang , Yuan Cheng
发明人： Wenge Zhong , Stephen Hitchcock , Vinod F. Patel , Michael Croghan , Thomas Dineen , Daniel Horne , Matthew Kaller , Charles Kreiman , Patricia Lopez , Holger Monenschein , Thomas Nguyen , Lewis Pennington , Qiufen Xue , Bryant Yang , Yuan Cheng
IPC分类号： A61K31/438 , C07D221/20 , C07D233/54 , A61K31/4178 , A61P25/28 , A61P25/00
CPC分类号： C07D491/107 , C07D221/06 , C07D311/96 , C07D471/10 , C07D491/10 , C07D493/10 , C07D495/10
摘要： The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein R1a, R1b, R1c, B, W, R3, R4 and R5 are defined herein. In another embodiment, the invention provides compounds of general Formula II wherein A1, A2, A3, A4, R1a, R1b, R1c, R2, R4, R5, W, X and Z are defined herein.The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease (AD), cognitive deficits and impairment, schizophrenia and other similar central nervous system conditions. The invention also comprises further embodiments of Formula II, intermediates and processes useful for the preparation of compounds of Formulas I and II.
摘要翻译：本发明包括可用于调节β-分泌酶酶活性和用于治疗β-分泌酶介导的疾病（包括阿尔茨海默病（AD））和相关病症的新一类化合物。在一个实施方案中，化合物具有通式I，其中R 1a，R 1b，R 1c，B，W，R 3，R 4和R 5在本文中定义。在另一个实施方案中，本发明提供通式II的化合物，其中A1，A2，A3，A4，R1a，R1b，R1c，R2，R4，R5，W，X和Z如本文所定义。本发明还包括在药物组合物中用于治疗，预防或治疗与β-分泌酶蛋白活性相关的病症和病症的用途。这些疾病包括例如阿尔茨海默病（AD），认知缺陷和损伤，精神分裂症和其他类似的中枢神经系统疾病。本发明还包括式II的其它实施方案，可用于制备式I和II化合物的中间体和方法。

9. 发明授权

US08957073B2 Unsaturated nitrogen heterocyclic compounds useful as PDE10 inhibitors 有权
标题翻译：用作PDE10抑制剂的不饱和氮杂环化合物
公开(公告)号：US08957073B2
公开(公告)日：2015-02-17
申请号：US13105860
申请日：2011-05-11
申请人： Jennifer R. Allen , Jian J. Chen , Michael J. Frohn , Essa Hu , Qingyian Liu , Alexander J. Pickrell , Shannon Rumfelt , Robert M. Rzasa , Wenge Zhong
发明人： Jennifer R. Allen , Jian J. Chen , Michael J. Frohn , Essa Hu , Qingyian Liu , Alexander J. Pickrell , Shannon Rumfelt , Robert M. Rzasa , Wenge Zhong
IPC分类号： C07D403/14 , A61K31/517 , C07D239/42 , C07D237/26 , A61K31/497 , C07D401/14 , C07D241/38 , C07D413/14 , A61K31/5355 , C07D405/14 , C07D409/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D487/04 , C07D491/08 , C07D487/08 , C07D487/10 , C07D491/107 , A61P3/04 , A61P7/12 , A61P25/18
CPC分类号： C07D401/14 , C07C53/18 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D471/08 , C07D487/04 , C07D487/08 , C07D487/10 , C07D491/056 , C07D491/08 , C07D491/107 , C07D513/04
摘要： Unsaturated nitrogen heterocyclic compounds of formula (I): as defined in the specification, compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, Huntington's Disease, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.
摘要翻译：式（I）的不饱和氮杂环化合物：如说明书中所定义，含有它们的组合物，以及制备这些化合物的方法。本文还提供治疗通过抑制PDE10可治疗的疾病或疾病的方法，例如肥胖症，亨廷顿舞蹈病，非胰岛素依赖性糖尿病，精神分裂症，双相障碍，强迫症等。

10. 发明授权

US08778941B2 TRPM8 antagonists and their use in treatments 有权
公开(公告)号：US08778941B2
公开(公告)日：2014-07-15
申请号：US13529880
申请日：2012-06-21
申请人： James Brown , Jian J. Chen , Vijay Keshav Gore , Scott Harried , Daniel B. Horne , Matthew R. Kaller , Qingyian Liu , Holger Monenschein , Thomas T. Nguyen , Nobuko Nishimura , Wenge Zhong
发明人： James Brown , Jian J. Chen , Vijay Keshav Gore , Scott Harried , Daniel B. Horne , Matthew R. Kaller , Qingyian Liu , Holger Monenschein , Thomas T. Nguyen , Nobuko Nishimura , Wenge Zhong
IPC分类号： C07D401/14 , C07D213/75 , C07D213/40 , C07D405/12 , C07D413/12
CPC分类号： C07D213/53 , C07C275/30 , C07D213/40 , C07D213/75 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12
摘要： Compounds of Formula I are useful as antagonists of TRPM8. Such compounds are useful in treating a number of TRPM8 mediated disorders and conditions and may be used to prepare medicaments and pharmaceutical compositions useful for treating such disorders and conditions. Examples of such disorders include, but are not limited to, migraines and neuropathic pain. Compounds of Formula I have the following structure: where the definitions of the variables are provided herein.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式